Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02198196
Other study ID # 1R21AT007845-01A1
Secondary ID
Status Completed
Phase N/A
First received July 21, 2014
Last updated February 3, 2016
Start date August 2014
Est. completion date January 2016

Study information

Verified date February 2016
Source Alere Wellbeing
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the efficacy of a phone-based weight loss program that has stress management techniques integrated throughout (Weight Talk-Mindfulness). The program is targeted at employees of certain companies who meet a cut-off score on a measure of stress-related eating. The control group will receive a standard phone-based program with no additional stress management information (Weight Talk-Standard).

- Hypothesis 1: Participants in Weight Talk-Mindfulness (WT-M; n=50) will experience decreases in their stress-related & emotion-related eating compared to the Weight Talk-Standard (WT-S; n=25) group.

- Hypothesis 2: The WT-M group will lose more weight compared to the WT-S control group.

- Hypothesis 3: Participants in WT-M will experience decreased perceived stress, increased eating self-efficacy, increased acceptance of weight-related thoughts & feelings and increased mindfulness compared to those in the WT-S control arm.

- Hypothesis 4: Participants in WT-M will be equally as satisfied with their weight loss program as those in WT-S.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Be enrolled in the Weight Talk program, inclusion criteria:

- Employment by one of the employers who contract for Weight Talk services

- Being over 18 years of age

- Speak and read English

- Have a starting BMI between 25 and 35.

- Score 5 or higher on the 8-item Internal Disinhibition subscale of the Eating Inventory.

- Have regular access to email and internet.

- Willingness and ability to complete study and intervention procedures, including completing assessments, engaging in moderate physical activity (e.g., walking, swimming) and using the electronic scale at least once per week.

Exclusion Criteria:

- Type 2 Diabetes (Type 1 is an exclusion for the Weight Talk program).

- Past diagnosis of anorexia nervosa or bulimia nervosa.

- Weight Talk program exclusion criteria include:

- Pregnancy

- Bariatric surgery within past 12 months or planned in the next 6 months

- Undergoing dialysis

- Have Type 1 Diabetes diagnosis

- Women who are pregnant are not eligible for the program, but contraception is not required as this is a low risk study

- Currently using or planning to start using a pharmaceutical weight loss drug

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Weight Talk-Mindfulness


Locations

Country Name City State
United States Alere Wellbeing, Inc Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Alere Wellbeing

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mindful Eating Questionnaire 28-item scale that measures non-judgmental awareness of physical and emotional sensations associated with eating. Screening, 6-month follow-up No
Other Rapid Fruit and Vegetable Screener 10-item scale that assesses fruit and vegetable intake. Screening, 6-month follow-up No
Other Fat Screener 17-item scale that assesses fat intake Screening, 6-month follow-up No
Other Sweets Eating 2-item scale that assesses high sugar food and drink intake Screening, 6-month follow-up No
Other Perceived Stress Scale - 4 item a 4-item scale that evaluates the appraisal of stress in one's life Screening, 6-month follow-up No
Other Binge Eating Scale 16-item scale that assesses the presence of binge eating behaviors. Screening, 6-month follow-up No
Other Behavioral Obesity Phenotype Scale 8-item scale that assesses lack of control, lack of satiation, and preoccupation with food. We include 6 out of the 8 original items; 2 of the items already exist in the Binge Eating Scale (BES). One additional Preoccupation with Food item was added. Screening, 6-month follow-up No
Other Acceptance and Action Questionnaire for Weight Related Difficulties 22-item scale that measures acceptance and flexibility in relation to problematic thoughts and feelings regarding weight. Screening, 6-month follow-up No
Other Generalized Anxiety Disorder scale 7-item diagnostic scale that assesses an individual's severity of anxiety and is used as a clinical screening tool for generalized anxiety disorder. Screening, 6-month follow-up No
Other Personal Health Questionnaire 2-item scale that assesses the frequency of depressed mood over the past 2 weeks and is used as a preliminary screening tool for depression. Screening, 6-month follow-up No
Other Adapted Physical Activity Measure 11-item scale that assesses overall activity level over the past week, adapted from measure used in the National Health and Nutrition Examination Survey (NHANES) Screening, 6-month follow-up No
Other Five Facet Mindfulness Questionnaire: Short Form 24-item scale that measures non-judgmental awareness of thoughts, feelings, and physical sensations. Screening, 6-month follow-up No
Other Satisfaction and Adherence 11-item measure consisting of Likert scale and open-ended questions about the participants' experience with the intervention and their adherence to mindfulness practice assignments. 6-month follow-up No
Primary Eating Inventory - Internal Disinhibition subscale 8 items, screens for emotion and stress-related eating habits Screening and 6-month follow-up No
Secondary Body weight Weight in pounds Screening and 6-month follow-up No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2